Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.32 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15545266 | 1.00 | GABRA1 (0.33) | GABRA1GABRB2HDAC3HDAC6RAPGEF3 | |
| SCHEMBL15544179 | 0.85 | HDAC8 (0.44) | HDAC3HDAC6SMN1; SMN2MEN1MAPT | |
| SCHEMBL15544177 | 0.85 | HDAC8 (0.44) | HDAC3HDAC6SMN1; SMN2MEN1MAPT | |
| SCHEMBL18856713 | 0.79 | SMN1; SMN2 (0.38) | HDAC3HDAC6SMN1; SMN2MEN1MAPT | |
| SCHEMBL18856778 | 0.79 | SMN1; SMN2 (0.35) | SMN1; SMN2MEN1KMT2AKDM4ENPC1 | |
| SCHEMBL15543683 | 0.78 | MAPT (0.38) | SMN1; SMN2MEN1MAPTKMT2AHTT | |
| SCHEMBL15543685 | 0.78 | MAPT (0.38) | SMN1; SMN2MEN1MAPTKMT2AHTT | |
| SCHEMBL17403486 | 0.77 | SLC13A3 (0.42) | HDAC3HDAC6RAPGEF3RAPGEF4SMN1; SMN2 | |
| SCHEMBL20194905 | 0.76 | PRKCI (0.34) | SMN1; SMN2MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL15544871 | 0.76 | IDO1 (0.37) | RAPGEF3RAPGEF4SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| EP-2870143-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
| WO-2014006066-A1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GABRA1 4135/4885GABRB2 4062/4885HDAC3 1386/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | GABRA1 4135/4885GABRB2 4062/4885HDAC3 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.